The National Organization for the Reform of Marijuana Laws has urged the Department of Health and Human Services to finalize the rescheduling of cannabis. The organization argues that removing the plant from its Schedule I classification is appropriate and long overdue. This move would acknowledge the legitimate therapeutic utility of the substance.
HHS acknowledged in 2023 that cannabis should be federally reclassified from Schedule I to Schedule III. NORML states that cannabis does not possess the same risks to health as other Schedule I substances like heroin. It also lacks the risks associated with unscheduled drugs like cigarettes and alcohol.
The advocacy group emphasizes that the United States should acknowledge the reality of cannabis as a medicine. To argue otherwise is out of step with both public opinion and scientific consensus. The organization believes the current federal stance is no longer defensible.
Survey data provided in May by researchers at the Johns Hopkins University School of Medicine shows strong professional support. More than 9 in 10 U.S. healthcare professionals support the legal medical use of cannabis. This data highlights the alignment between medical practice and potential federal policy.
Additional polling analyzed by researchers from the Centers for Disease Control and Prevention provides further context. More than one-quarter of clinicians surveyed had recommended cannabis to their patients. These figures demonstrate widespread integration of cannabis into clinical recommendations.
The review found cannabis is effective in treating chronic pain and other serious health conditions. This scientific backing supports the argument for a lower schedule classification.
Other nations around the world acknowledge cannabis as a legitimate medicine and regulate it accordingly. The United States is currently out of step with these international regulatory frameworks. NORML points to this global trend as evidence of the need for domestic change.
A version of this commentary originally appeared in The Washington Post. It was written in response to the op-ed “This marijuana disaster could rival Big Tobacco.” The publication serves as a platform for this specific policy argument.
Additional information on rescheduling and its implications for state and federal marijuana policies is available from the NORML Fact Sheet. The document is titled “Cannabis Rescheduling: Myths Versus Reality.” This resource provides further details on the proposed regulatory shift.
Expert Warning On Outdated Testing Dr Georges Petitjean has warned that workplace drug testing has failed to keep pace with…
Event Details Shore House Canna, an adult-use dispensary in West Cape May, New Jersey, will host its 3rd Annual Fall…
Sabalenka Stops Play Over Cannabis Smell Top seed Aryna Sabalenka briefly halted her US Open third-round match against Kamilla Rakhimova…
CBDD Signs Definitive Agreement to Acquire BioCannabis CBD of Denver, Inc. (OTCID: CBDD) announced on September 15, 2026 that it…
Seventh Annual New Jersey Cannabis Convention Set NECANN brings the New Jersey Cannabis Convention back to the Atlantic City Convention…
The Violation Vermont Lt. Gov. John Rodgers plans to pay a reduced fine to settle a case involving an unlicensed…
